Pharmaceutical Industry Enjoys Temporary Relief from Tariffs, but Challenges Loom Ahead
In recent weeks, there has been considerable speculation surrounding the impact of Donald Trump’s significant tariff policy shift on the pharmaceutical sector. It was somewhat surprising to discover that drug products were notably absent from the 20% tariffs set to apply to exports from the EU to the US.
Tánaiste Simon Harris has indicated that the White House may soon introduce measures specifically targeting pharmaceutical products, potentially in the coming weeks. “We are keeping a close eye on these developments,”…